

Press Release

for Immediate Release

Q1FY25 Revenue from operations at INR 11,799 Mn. up 20% YoY, EBITDA at INR 2,593 Mn. up 89% YoY, PAT at INR 1,346 Mn. up 181% YoY.

Hyderabad, India, July 30, 2024: Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter and financial year ended June 30, 2024.

Financial Summary (All numbers in INR Mn., except Margins)

QUARTERLY CONSOLIDATED FINANCIALS	Q1FY25	Q4FY24	Growth (QoQ)	Q1FY24	Growth (YoY)
Revenue from Operations	11,799	11,758	0%	9,855	20%
EBITDA	2,593	2,557	1%	1,368	89%
EBITDA %	22%	22%		14%	
PAT	1,346	1,296	4%	479	181%
PAT %	11%	11%		5%	

Financial and Business Summary for Q1FY25

- Revenue from Operations of Q1FY25 stood at INR 11,799 Mn., a growth of 20% YoY.
- Revenue share from the North America increased to 74% in Q1 FY25 as compared to 61% in Q1 FY24.
- Decline in Para API and PFI sales volume and price erosion.
- Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Finished dosages contribute 14%, 10%, and 76% of revenue from operations respectively for Q1FY25.
- ROCE is at 19.6% as compared to 9.3% YoY.
- Net debt stood at INR 7,941 mn and Net debt to EBITDA at 0.77x.

Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “With our robust quarterly performance, we are back on our planned trajectory after a few setbacks last year. Q1 performance highlights include continued growth in our formulation segment, strong North America business, and product diversification, which offset the Paracetamol API/PFI decline, promising a brighter future driven by our formulations offering and new product pipeline.”

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and UK. The Company has 10 manufacturing facilities out of which 8 are in India and 2 in the USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.

Safe Harbor

This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, and/or regulatory factors. Granules India Ltd., its directors, and any of the affiliates or employees are under no obligation to and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:	
Granules IR Desk investorrelations@granulesindia.com	Chaitanya Tummala 040-69043614 Company Secretary chaitanya.tummala@granulesindia.com